Apiam Animal Health Limited (ASX:AHX) is pleased to announce the acquisition of Harradine & Associates, a large veterinary business located in the southwest region of Western Australia.
VGI Health Technology Limited (NSX:VTL) is pleased to announce that its wholly owned subsidiary, Invictus Ops Pty Ltd (Invictus), has commenced dosing of patients for its Phase II clinical study in Non-Alcoholic Fatty Liver Disease.
Apiam Animal Health Limited (ASX:AHX) is pleased to announce the appointment of Ms Evonne Collier as a Non-Executive Director to the Company's Board of Directors, with effect from 1 October.
VGI Health Technology Limited (NSX:VTL) is pleased to announce that its wholly owned subsidiary, Invictus Ops Pty Ltd (Invictus), has received ethics approval to proceed with a US pharmacokinetics and exercise clinical study.
VGI Health Technology Limited (NSX:VTL) is pleased to announce that its wholly owned subsidiary, Invictus Ops Pty Ltd (Invictus), has made significant progress in its Phase II clinical study in Non-Alcoholic Fatty Liver Disease (NAFLD)/Non-Alcoholic SteatoHepatitis (NASH).
Apiam Animal Health Limited (ASX:AHX) MD Dr. Chris Richards speaks with ABN Newswire regarding the Financial Year 2022 results, the accelerated growth strategy and looking ahead to 2023.
Apiam Animal Health Limited (ASX:AHX) is pleased to release its full year results for the 12-months to 30 June 2022 (FY22).
